Beijing Danatlas Pharmaceutical Technology Co. Ltd. has disclosed poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Hangzhou Synrx Therapeutics Biomedical Technology Co. Ltd. recently presented the development and characterization of a novel PARG inhibitor, SYN-608, for the potential treatment of tumors with/without homologous recombination deficiency (HRD).
Nodus Oncology Ltd. presented the discovery of NODX-010, a potent poly(ADP-ribose) glycohydrolase (PARG) inhibitor being developed for the potential treatment of cancer, including tumors resistant to PARP inhibitors.
Recent Ideaya Biosciences Inc. patents describe new poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Ideaya Biosciences Inc. has described piperazine substituted indazole compounds acting as poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
Shanghai Yingli Pharmaceutical Co. Ltd. has described poly(ADP-ribose) glycohydrolase (PARG) inhibitors reported to be useful for the treatment of cancer.
